Back to Search
Start Over
In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations.
- Source :
-
Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2015 Mar; Vol. 59 (3), pp. 1789-93. Date of Electronic Publication: 2014 Dec 22. - Publication Year :
- 2015
-
Abstract
- Avibactam, a broad-spectrum β-lactamase inhibitor, was tested with ceftazidime, ceftaroline, or aztreonam against 57 well-characterized Gram-negative strains producing β-lactamases from all molecular classes. Most strains were nonsusceptible to the β-lactams alone. Against AmpC-, extended-spectrum β-lactamase (ESBL)-, and KPC-producing Enterobacteriaceae or Pseudomonas aeruginosa, avibactam lowered ceftazidime, ceftaroline, or aztreonam MICs up to 2,048-fold, to ≤4 μg/ml. Aztreonam-avibactam MICs against a VIM-1 metallo-β-lactamase-producing Enterobacter cloacae and a VIM-1/KPC-3-producing Escherichia coli isolate were 0.12 and 8 μg/ml, respectively.<br /> (Copyright © 2015, American Society for Microbiology. All Rights Reserved.)
Details
- Language :
- English
- ISSN :
- 1098-6596
- Volume :
- 59
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Antimicrobial agents and chemotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 25534728
- Full Text :
- https://doi.org/10.1128/AAC.04191-14